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 Abstract  
Bioprospecting is a controversial issue, and anthropologists and other scientists are quick 
to take sides. The idea of large corporations pumping money into conservation and development 
programs, while developing what could be the latest life-saving drug simply sounds too good to 
be true, and often times is. However, if all parties work together and proceed with caution, these 
benefits could become more than a fantasy. Looking at case studies from Costa Rica, India, 
South Africa and Panama this paper attempts to find patterns among successful bioprospecting 
agreements and note shortcomings and identify risks. This information will be used to suggest 
how indigenous communities can maximize benefits while protecting their rights in 
bioprospecting relationships.  
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Introduction 
 
Biodiversity prospecting, or bioprospecting, is “the exploration of biological material for 
commercially-valuable genetic and biochemical properties” (Laird and Wynberg 2008). 
Bioprospecting is used by a number of industries, from cosmetics to agriculture to 
biotechnology. The focus of this thesis is on the role of bioprospecting in the pharmaceutical 
industry. Currently, a large number of drugs on the market require natural-compounds for their 
production. In fact, “a third of the products that comprise the US$ 200 billion plus prescription 
drug industry” (Onaga 2001) are naturally based compounds, meaning they came from plants, 
invertebrates, fungi or microorganisms. The majority of these compounds are found in areas of 
high biodiversity, such as rainforests or coral reefs, typically located in Third World countries 
along the equator or in the Southern Hemisphere, where a high concentration of remaining 
indigenous populations live. 
 There is a long history of the wealthier northern hemisphere companies taking advantage 
of its neighbors in the South leading some anthropologists to wonder if bioprospecting is just 
another form of colonialism, or “bioimperialism” (Moran, King and Carlson 2001). Shiva (2007) 
argues that bioprospecting is simply a sophisticated form of “biopiracy”, a practice that “creates 
impoverishment within donor communities by claiming monopolies on resources… and forces 
communities to pay for what was originally theirs.” 
International agreements have been developed in recent years to protect the traditional 
knowledge of local peoples. The Convention on Biological Diversity (CBD) has had a particular 
focus on the legal issues concerning bioprospecting (Kursar et al. 2006). According to Zedan 
(2005), “the Convention is the first international instrument to take a holistic view of the 
conservation of biological diversity by integrating ecological, social, and economic perspectives. 
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Indeed, the core bargain between the North and the South in the negotiation of the Convention is 
the South’s commitment to conserve biological diversity and the North's to share in the costs and 
benefits of sustainable use.” The CBD serves to ensure that developing countries benefit from 
the “exploitation of their genetic resources” (Zedan 2005). 
Pharmaceutical companies have an economic interest in protecting areas of high 
biodiversity, as these areas are most likely to produce the compounds that could be used in future 
drugs, and thus future profits for drug corporations. If proper regulations are in place, local 
indigenous people may also gain from benefit-sharing agreements and new technologies brought 
into the country from pharmaceutical companies and their profits.  An example of a positive 
benefit-sharing approach is Merck’s contractual agreement with Costa Rica’s National 
Biodiversity Institute (INBio). Under the agreement, Merck paid $1 million over two years to 
INBio for the right to collect soil, insect and plant samples. INBio scientists process the samples 
before sending them to researchers at Merck, who then test the samples for chemical activity. “If 
INBio can create more jobs, profits, and a better-educated constituency by cataloging and selling 
rights to the country's natural resources than by destroying its resources, it makes economic 
sense to keep the resources intact” (Blum 1993). This approach has been fairly limited thus far, 
but could be modified for further research.  
In contrast to the success of INBio and Merck’s agreement, consultations between South 
Africa’s Council for Scientific & Industrial Research (CSIR) and the San of the Kalahari Desert, 
which is the oldest surviving ethnic group living in Southern Africa, paint a less rosy picture of 
bioprospecting. In the late 1990s, the CSIR began negotiations with US pharmaceutical giant 
Pfizer to commercialize the appetite suppressant qualities of a flowering, cactiform plant, Hoodia 
gordonii. This plant is important to the culture of the San and has been used traditionally for 
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thousands of years.  The negotiations began without involving the San. The two parties did 
eventually sign a benefits-sharing agreement, although it is often met with criticism for limiting 
the San’s legal claim on Hoodia and providing little in terms of actual payout (Wynberg 2004). 
These two examples indicate that bioprospecting has potentially significant benefits to 
alleviate poverty and to protect areas of the world’s richest biodiversity. However, 
bioprospecting also can be viewed as just another way for the modern capitalist economy to 
exploit indigenous populations. The purpose of my thesis is to examine four specific cases from 
the literature and conduct a comparative analysis of the potential impact of bioprospecting on 
indigenous people and specifically address the degree to which prospectors have negotiated or 
have not negotiated with native peoples, how agreements have been forged, what role national 
governments played in the agreements, how native people have profited, and how profits have 
been used by native peoples. 
Materials and Methods 
 The issue of bioprospecting and benefits-sharing is broad. To narrow the focus of this 
paper, four case studies were looked at in depth. These studies were chosen because they 
represented a spectrum of user/provider relationships and they each showed a unique approach 
and result.  Studies from South Africa, Costa Rica, Panama and India were examined. These 
studies were readily available in the literature and provided different perspectives on the issue.  
The cases also show both positive and negative consequences from which suggestions will 
developed as to how future bioprospecting agreements can maximize benefits and minimize risks 
for local parties.  
 The provider community is not indigenous in each example, though that is where the 
focus of the thesis lies. The current working definition provided by the UN states, “Indigenous 
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communities, peoples and nations are those which, having a historical continuity with pre-
invasion and pre-colonial societies that developed on their territories, consider themselves 
distinct from other sectors of the societies now prevailing on those territories, or parts of them. 
They form at present non-dominant sectors of society and are determined to preserve, develop 
and transmit to future generations their ancestral territories, and their ethnic identity, as the basis 
of their continued existence as peoples, in accordance with their own cultural patterns, social 
institutions and legal system.” There are unique challenges that indigenous people face that other 
local communities may not, yet most of the successful relationships that appear in the literature 
did not involve indigenous populations. There may still be something to learn from the 
arrangements between non-indigenous local peoples and drug companies, though it may take 
additional assistance for marginalized indigenous peoples to reach similar success.   
Results 
 
A general summary of the results in the context of the party’s involved, the negotiation 
process, role of Government/NGOs, and the monetary and non-monetary benefits to the local 
community are summarized in Table 1. Details for each case are provided in the following 
paragraphs.  
 
South Africa: The San and Hoodia 
The San of the Kalahari Desert are the oldest surviving ethnic group living in Southern 
Africa.  Today they live in parts of South Africa, Namibia, Angola and Botswana. They have 
been using Hoodia as a thirst and hunger suppressant for thousands of years, a practice which 
drew the attention of researchers in the 1960s.  At this time, South Africa’s Council for Scientific 
& Industrial Research (CSIR) began studying the plants properties and ultimately filed to patent 
the “discovery” of its appetite-suppressant qualities in 1996. 
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The CSIR began negotiations with Pfizer to commercialize the drug, without first 
consulting the San. In fact the CSIR was quoted in a newspaper article “having told their 
international collaborators that the 90,000-strong San ‘no longer existed’” (Wynberg 2004). 
Fortunately, NGOs Biowatch South Africa and Action Aid stepped in and alerted the media to 
exclusion of the San from the Hoodia negotiations in 2001 (Wynberg 2004). International 
pressures served as a catalyst to get the San involved in the agreements. In 2003, the CSIR and 
the San sign a benefit-sharing agreement. However, the San received no legal or strategic aid in 
the negotiation process and their requests for training and assistance were denied. The San, a 
traditionally egalitarian society, were “pressured by NGOs, donors and governments to organize 
themselves and appoint leaders” (Vermeylen 2007). The procedure ignored the San’s traditional 
decision-making process and they were expected to “organize themselves in such a way that it 
was easier for the CSIR to deal with them” (Vermeylen 2007). By encouraging the San to 
function in a way that was familiar to Western culture, a group of San elites rose to power that 
previously had not been there. This new high status often came from the ability to speak 
Afrikaans, the language of the outside world. This new hierarchy created a great deal of tension 
among the San, who had always made their decisions through discussion and consensus. Using 
this system, however, only a small, select few voices were heard from an already marginalized 
people, yet very few living outside of South Africa were even aware of the proceedings with the 
CSIR. A lack of communication and full community consent plagued the negotiation process.  
The treatment of the San was not the only concern regarding this agreement. In fact, the 
case of the Hoodia plant pokes many holes in the entire benefit-sharing system. Without 
assistance in the negotiation process, the San and the CSIR reached an agreement that the San 
would receive six percent of royalties and eight percent of all milestone payments that CSIR 
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collects from the sale of Hoodia (Vermeylen 2007). Wynberg (2004) estimates that this would 
account for approximately 0.03 to 1.2 percent of the products net sales. This money would be 
divided equally among the four countries the San are living in, and used for development 
projects and to fund the San Council. Unfortunately, the commercialization of Hoodia hit some 
roadblocks. Pfizer dropped out of the project in 2004, when Unilever picked it up, hoping to sell 
it as a supplement rather than a prescription drug (Vermeylen 2007). This dramatically cut the 
profit margin. In the 2008 Sustainable Development Overview, released a year after Vermeylen 
published his study, Unilever too backed out of plans to use Hoodia in diet products after 
investing 20 million Euros. In its Sustainable Development Overview Unilever reports, 
“Innovation also carries uncertainties and does not always lead to positive outcome… We 
stopped the project because our clinical studies revealed that products using Hoodia would not 
meet our strict standards of safety and efficacy” (Unilever 2008).   
Although the project fell through, under their agreement with the CSIR, the South 
African San were prevented from “using their knowledge of Hoodia in any other commercial 
applications…(and) to claim any benefits from the dozens of new Hoodia-based products that 
have recently emerged in the market, which blatantly use San traditional knowledge of Hoodia in 
their promotion” (Wynberg 2004).   
Perhaps it would have been more viable for the San to pursue options based on non-
patented herbal medicines (Wynberg 2004), Thomas Kursar and his colleagues agree that 
monetary benefits should not be the focus of negotiations, stating, 
Because the success rate for drug discovery is exceedingly low, financial benefits, such 
as milestone payments or royalties, are highly unlikely. Furthermore in the case of 
royalties, the time frame is long, perhaps 10 to 12 years from discovery to receiving 
benefits. Thus this model, with the source country offering biological materials and the 
developed country supplying research, provides few or no benefits for the source country 
(Kursar et al. 2006). 
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The San did not know that they could pursue non-monetary benefits, as established in an 
addition to the CBD, known as the Bonn guidelines. The Bonn guidelines, added in 2002, 
include “benefits such as access to and transfer of technology, training and joint research, 
acknowledging sources, reporting research results, scientific cooperation, institutional capacity-
building, employment opportunities and ongoing relationships” (Vermeylen 2007). Had the San 
been informed about the non-monetary benefits, they might have more to show from their 
negotiations with the CSIR. 
Costa Rica: INBio and Merck 
 The negotiations and agreements that took place between Merck and the Instituto 
Nacional de Biodiversidad de Costa Rica (INBio) were of a very different form than those that 
occurred in South Africa between the San and the CSIR. Despite their differences, there are 
similarities between the two and there is something to be learned from comparing cases on both 
ends of the spectrum. Costa Rica’s high biodiversity and natural beauty is world renowned, yet it 
is at high risk of being destroyed as development pushes forward.  One reason for this 
destruction is the “incompatibility of short-term economic growth with the sustainable 
development of natural resources” (Blum 1993). Blum (1993) continues, “When an 
economically struggling country has a choice between logging a forest to sell timber for high 
profits and leaving the forest intact without monetary compensation, the nation usually chooses 
the profitable alternative. Because immediate economic gains to the nation are more important 
than future environmental costs, deforestation occurs without regard to its long-term effects on 
biodiversity preservation.” Faced with this common challenge, researchers in Costa Rica came 
up with an uncommon solution; partnering with a multinational company.  
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 INBio is “a private research and biodiversity management center, established in 1989 to 
support efforts to gather knowledge on the country’s biological diversity and promote its 
sustainable use. The institute works under the premise that the best way to conserve biodiversity 
is to study it, value it, and utilize the opportunities it offers to improve the quality of life of 
human beings” (INBio 2011). They are non-profit and non-governmental. In 1991 they teamed 
up with Merck to protect biodiversity and promote the discovery of new compounds that may be 
used in drugs. INBio received $1 million dollars from Merck over 2 years, plus 5 percent of 
royalties on the sales of any products developed from samples found in the study area. Costa 
Rica’s Ministry of Natural Resources, Energy and Mines will receive money from the agreement 
as well, $100,000 from INBio and 50 percent of any royalties. This money will be used for 
biodiversity conservation projects throughout the country (Gershon 1992). 
 By putting money into a private research institution, the Merck-INBio agreement is 
helping to provide jobs for scientists allowing them to stay in their home country and is 
strengthening the economy by keeping research and development jobs in Costa Rica. Although 
no drugs from this deal have made it to the market yet, Merck claims that a number have “market 
potential” (Cullen 2008).   
 Of course the agreement is not without its flaws. One of the main criticisms of the 
arrangement is that INBio is private, and dispute the organization’s power to make decisions for 
the country, arguing, “INBio has no right and no authority to represent Costa Rica” (Gershon 
1992). Many also believe that the Costa Rican government should get a bigger cut of INBio’s 
payment from Merck. However, these criticisms have not stood in the way of the deal being 
renewed in 1994, 1996 and 1998 (Cullen 2008).  
Panama: Collaboration with the International Cooperative Biodiversity Group (ICBG) 
Comment [dcg1]: You need to make 
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One of the problems with traditional bioprospecting benefit-sharing agreements is the 
provider country’s dependence on a raw material. Exporting raw biotic resources generates little 
revenue for a source country. Value is added when the material becomes a commercial product. 
By basing research in the host country, its economy will benefit from new jobs, training and 
infrastructure, improvements in scientific capacity, policymaking, resource management, 
tourism, conservation, and perhaps even start-up biotech companies (Kursar et al. 2006). In the 
late 1990s a team of researchers collaborated with the International Cooperative Biodiversity 
Group (ICBG) of Panama in an attempt to prove that drug discovery, conservation and economic 
development could go hand in hand. The partnership’s goal was to ensure that Panama “receives 
immediate advantages from bioprospecting” (Kursar et al. 2006). Similar to the Merck-INBio 
agreement, the collaboration between the ICBG and Panama went beyond monetary benefit-
sharing and worked to incorporate infrastructure for more long-term economic development.  
Using funds from the ICBG and the Smithsonian Institute two new laboratories were 
built in Panama and several others were updated. Research is done on over 100 compounds, 
searching for new cancer fighting drugs, as well as treatments for tropical diseases. These new 
facilities not only provide jobs for Panamanian scientists, but also research experience for the 
students. They also bring in about $500,000 a year for Panama. Although outside help is required 
to get started, “a self-sustaining research capacity can be developed in a relatively short time, 
such that investigators can independently obtain their own funding” (Kursar et al. 2006).   
Kursar et al. (2006) argues that, “one of the more remarkable characteristics of 
bioprospecting is that issues of great importance that are often at odds- conservation, sustainable 
economic development, and human health- become interconnected and mutually beneficial.” 
Comment [dcg2]: This should be 
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Following their work in Panama, Kursar and his colleagues conclude that bioprospecting 
deserves “strong encouragement at both the national and international levels.”  
The ICBG has projects outside of Panama, as well, that have achieved varied levels of 
success. However, anthropologist Shane Greene writes, “Of the eight ICBG grants awarded, the 
two that were clearly the most controversial, ICBG-Aguaruna and ICBG-Maya, entailed direct 
negotiations between indigenous peoples and bioprospectors and the intervention of interested 
third-party NGOs claiming to act on behalf of or in conjunction with those indigenous peoples” 
(2004).  
India: Community-based Enterprise, Rural Farmers and the GMCL 
Like the Panamanians, communities in India are interested in linking bioprospecting to 
economic development for marginalized people. Without outside funding, the Indians turned to a 
bottom-up approach, developing a community-based enterprise, called Gram Mooligai Company 
Limited (GMCL), which “supplies medicinal herbs to pharmaceutical enterprises playing an 
intermediary role between these companies and the local farmers, and it commercializes 
ayurvedic medicines produced by local communities under the brand of ‘VillageHerbs’” (Torri, 
2009).  
 The GMCL is composed of a number of small village organizations or Sanghas. Each 
Sangha is composed of no more than 20 (usually between 10 and 15) members, who are all 
women and all of the same socio-economic and caste background. This homogeneity helps to 
prevent conflicts within the group and encourages joint decision-making. The majority of the 
members are landless, and the program relies heavily on social capital to run smoothly. The 
women in the Sanghas are herb gatherers and collectors. They collect 17 medicinal plant species 
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from fallow farms, barren land and wetland banks. The GMCL also promotes the cultivation of 5 
species, as well as teach the use organic farming methods (Olaganathan et al. 2005).  
When the GMCL negotiates a deal with a pharmaceutical company, they offer the order 
to the Sanghas who will then collect the herbs for 70 percent of the buyer’s negotiated price. 
This system produces a modest income for poor families that has the potential to continue to 
grow. It has proven to recognize and protect medicinal plants, restore faith in traditional 
knowledge in ethnomedicine and makes rural healthcare available to over 3,000 families 
(Olaganathan et al. 2005). The program also empowers women by improving their social 
standing. The success of the GMCL has “increased their sense of identity and their 
empowerment as a community” (Torri, 2009). 
 Discussion  
Negotiation Progress 
 The negotiation process varied significantly between the four cases studied (Table 1). 
Clearly, the situation the San faced with the CSIR was less than ideal. They were not respected 
throughout the decision making progress and the proper assistance was not available to them. 
This early example of a benefit-sharing agreement points out flaws in the system and to the 
importance of open communication between all parties involved.  
In Costa Rica and Panama the negotiation process looked very different. In both of these 
examples, decisions were made with assistance from outside forces, and the help of the national 
government. Also in these cases, the providers were involved in the negotiation process from the 
beginning. Even so, in the Merck-INBio agreement in Costa Rica, not all were happy with the 
final agreements (Gershon 1992). The case in India between the Sanghas, the GMCL and 
national and international drug companies is different still. This approach included more 
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community-involvement. Because the GMCL is owned by the women who collect herbs for it, 
there is less clash of interest as the two parties are working for the success of the project.  
Benefits to Local Community 
 As one would expect, each arrangement produced very different results. Each case had 
pros and cons, unique of course to the situation at hand. The studies in South Africa and Costa 
Rica both included a benefit-sharing agreement with a pharmaceutical company. In both cases, a 
long negotiation process established the percentage of royalties and any additional milestone 
payments the local peoples would receive from the sale of products addressed in the legal 
agreements. Royalty agreements are criticized because until the pharmaceutical company in the 
negotiations produces a drug that goes to market, there are no royalties for the provider 
communities. If drugs never surface from the deal the local peoples never receive royalties. 
Another criticism of the benefit-sharing approach is if the drug does become available for sale, 
and hits it big for the pharmaceutical company, then the percentage of the royalties agreed upon 
may seem insignificant.  
 In Costa Rica the benefits from the agreement between INBio and Merck were not only 
through royalties. Perhaps more importantly, they received initial payments from Merck for 
conservation and were given an opportunity to improve their scientific capacity. In both Costa 
Rica and Panama the benefits seem to be more long-term. Both arrangements provided 
significant opportunity for economic development through R&D and encourage conservation. 
Critics argue that this is not an all-encompassing approach to dealing with bioprospecting and 
may not work well in other Latin American countries or in other nations around the world. 
“INBio can be one model, but it shouldn’t be the only model” (Gershon 1992). 
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The idea of going beyond benefit-sharing and royalty agreements however is more 
universal. In the past decade “the importance of non-monetary benefits has increasingly been 
recognized” (Wynberg 2004).  Rather than waiting around for a royalty’s check that may or may 
not arrive, the communities that experienced the most success built bioprospecting into their 
economy and way of life. This approach was used in India, sustainable bioprosepecting was 
introduced to the community and while the potential rewards may not have been as grand as in 
some of the other scenarios, the risks were minimized and the benefits were more stable. 
Shortcomings and Suggestions for Improvement 
A shortcoming in the literature is acknowledging the different issues and needs of 
indigenous peoples compared to those of local peoples. This distinction is underrepresented in 
the literature and is missing from much of the regulation regarding bioprospecting. In some ways 
comparing the specific needs of indigenous peoples to those of the general public of developing 
countries is mixing apples and oranges. Indigenous peoples are often marginalized within their 
home countries and may not have access to the same resources, yet there could still be something 
to learn from such cases. At the very least it could point to areas in which indigenous groups may 
need to seek addition help. Fortunately, there are a number of NGOs that support indigenous 
peoples rights and help communities sort through legalities and better negotiate with Western-
minded corporations. Today, bioprospecting is characterized by misunderstanding, mistrust, and 
regulatory confusion. Further research could improve understanding of the risks of 
bioprospecting and its potential benefits 
The only constant throughout all cases is that there is no one model that communities can 
follow to maximize their benefits and minimize their risks from bioprospecting. However, those 
who had the most success were those who took advantage of the opportunity to become involved 
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with the process and create local infrastructure to further research and development of the 
drugs. Those who sit back and wait for royalties maybe disappointed with the amount they end 
up receiving from the sale of the drug. When the providers receive monetary benefits, they risk 
unequal distribution or reward throughout community. Negotiating for non-monetary benefits, 
such as schools, hospitals or protected areas can mitigate this problem.  
Conclusions 
 The cases in which there was the most success shared some traits. These shared traits 
could be a part of a collaboration model. The characteristics of successful collaboration are 
identified by Friend and Cook (1996) as collaboration being voluntary, based on parity, working 
for a shared goal, having shared responsibility and accountability, based on shared resources and 
emergence. Of the studies looked at, the GMCL’s work with rural Indian farmers seemed to 
include the best collaboration. All parties were involved from the beginning and were able to 
voice their concerns. The economic benefits are consistent and the arrangement respects the 
traditional society.  
 Though there is not one model that can be use for every bioprospecting arrangement, 
there are characteristics that should be present in all cases. All parties need to be involved from 
the beginning of the decision-making progress. There needs to be a respect for all parties and 
assistance from NGOs and other aids should be available. Provider communities need to be made 
aware of all of their options, monetary and not. Open communication and trust is key.  
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